Clinical Potential of Advanced Glycation End-Product Inhibitors in Diabetes Mellitus

Author： Menè P.   Festuccia F.   Pugliese F.  

Publisher： Adis International

ISSN： 1175-3277

Source： American Journal of Cardiovascular Drugs, Vol.3, Iss.5, 2003-01, pp. : 315-320

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Antibodies to advanced glycation end products in children with diabetes mellitus

By Nicoloff G.   Baydanoff S.   Petrova C.   Christova P.  

General Pharmacology, Vol. 39, Iss. 1, 2002-07 ,pp. : 39-45

Elsevier

Access to resources Recommend Favorite

Phase I Clinical Studies of the Advanced Glycation End-product (AGE)-Breaker TRC4186: Safety, Tolerability and Pharmacokinetics in Healthy Subjects

By Chandra Kumar P.  

Clinical Drug Investigation, Vol. 29, Iss. 9, 2009-09 ,pp. : 559-575

Adis International

Access to resources Recommend Favorite

Advanced Glycation Endproduct Crosslinking in the Cardiovascular System: Potential Therapeutic Target for Cardiovascular Disease

By Zieman S.J.   Kass D.A.  

Drugs, Vol. 64, Iss. 5, 2004-01 ,pp. : 459-470

Adis International

Access to resources Recommend Favorite

Role of Advanced Glycation End Products (AGEs) in Osteoporosis in Diabetes

By  

Current Drug Targets, Vol. 12, Iss. 14, 2011-12 ,pp. : 2096-2102

Bentham Science Publishers

Access to resources Recommend Favorite

Telmisartan, an Angiotensin II Type 1 Receptor Blocker, Inhibits Advanced Glycation End-product (AGE)-elicited Hepatic Insulin Resistance via Peroxisome Proliferator-activated Receptor-γ Activation

By Yoshida T   Yamagishi S   Matsui T   Nakamura K   Ueno T   Takeuchi M   Sata M  

The Journal of International Medical Research, Vol. 36, Iss. 2, 2008-03 ,pp. : 237-243

Field House Publishing

Access to resources Recommend Favorite